Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| UNITED THERAPEUTICS CorpUTHR · Entity 664 | CFO AND TREASURER | June 22, 2026 | June 23, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
UNITED THERAPEUTICS Corp
Report date June 22, 2026 · Filed June 23, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 18,876 |
Ending reported balance
After 2026-06-22 transaction · row 9
9 source rows · reconciled sequenceRow 1 · 2026-06-22 · Exercise / conversion · Acquired 8,750 · Balance 27,626 F1: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on October 31, 2025. Row 2 · 2026-06-22 · Sale · Disposed 164 · Balance 27,462 F1: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on October 31, 2025. F2: This transaction was executed in multiple trades at prices ranging from $533.57 to $534.53. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Row 3 · 2026-06-22 · Sale · Disposed 865 · Balance 26,597 F1: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on October 31, 2025. F3: This transaction was executed in multiple trades at prices ranging from $534.57 to $535.56. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Row 4 · 2026-06-22 · Sale · Disposed 1,091 · Balance 25,506 F1: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on October 31, 2025. F4: This transaction was executed in multiple trades at prices ranging from $535.64 to $536.47. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Row 5 · 2026-06-22 · Sale · Disposed 840 · Balance 24,666 F1: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on October 31, 2025. F5: This transaction was executed in multiple trades at prices ranging from $536.65 to $537.59. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Row 6 · 2026-06-22 · Sale · Disposed 2,266 · Balance 22,400 F1: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on October 31, 2025. F6: This transaction was executed in multiple trades at prices ranging from $537.67 to $538.66. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Row 7 · 2026-06-22 · Sale · Disposed 1,994 · Balance 20,406 F1: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on October 31, 2025. F7: This transaction was executed in multiple trades at prices ranging from $538.67 to $539.66. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Row 8 · 2026-06-22 · Sale · Disposed 280 · Balance 20,126 F1: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on October 31, 2025. F8: This transaction was executed in multiple trades at prices ranging from $539.68 to $539.92. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Row 9 · 2026-06-22 · Sale · Disposed 1,250 · Balance 18,876 F1: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on October 31, 2025. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $146.03 · Expires 2027-03-15 | Direct | 0 |
Reported balance
After 2026-06-22 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2026-06-22 · Exercise / conversion · Disposed 8,750 · Balance 0 F1: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on October 31, 2025. |
Filing footnotes · ownership attribution and instrument terms
F1: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on October 31, 2025.
F2: This transaction was executed in multiple trades at prices ranging from $533.57 to $534.53. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F3: This transaction was executed in multiple trades at prices ranging from $534.57 to $535.56. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F4: This transaction was executed in multiple trades at prices ranging from $535.64 to $536.47. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F5: This transaction was executed in multiple trades at prices ranging from $536.65 to $537.59. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F6: This transaction was executed in multiple trades at prices ranging from $537.67 to $538.66. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F7: This transaction was executed in multiple trades at prices ranging from $538.67 to $539.66. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F8: This transaction was executed in multiple trades at prices ranging from $539.68 to $539.92. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 30, 2026 Filed May 1, 2026 20:56 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 336 | $577.24 | $193,951.70 |
DisclosureSEC source: 0001636178-26-000014 · primarydocument.xml · nonDerivative · entry 10 EDGEMOND JAMES · CIK 0001636178 · CFO AND TREASURER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 19,294 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on October 31, 2025. F10 · price: This transaction was executed in multiple trades at prices ranging from $576.75 to $577.72. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 30, 2026 Filed May 1, 2026 20:56 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 486 | $576.24 | $280,052.98 |
DisclosureSEC source: 0001636178-26-000014 · primarydocument.xml · nonDerivative · entry 9 EDGEMOND JAMES · CIK 0001636178 · CFO AND TREASURER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 19,630 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on October 31, 2025. F9 · price: This transaction was executed in multiple trades at prices ranging from $575.73 to $576.72. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 30, 2026 Filed May 1, 2026 20:56 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 273 | $574.96 | $156,965.25 |
DisclosureSEC source: 0001636178-26-000014 · primarydocument.xml · nonDerivative · entry 8 EDGEMOND JAMES · CIK 0001636178 · CFO AND TREASURER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 20,116 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on October 31, 2025. F8 · price: This transaction was executed in multiple trades at prices ranging from $574.61 to $575.57. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 30, 2026 Filed May 1, 2026 20:56 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 887 | $574.07 | $509,195.92 |
DisclosureSEC source: 0001636178-26-000014 · primarydocument.xml · nonDerivative · entry 7 EDGEMOND JAMES · CIK 0001636178 · CFO AND TREASURER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 20,389 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on October 31, 2025. F7 · price: This transaction was executed in multiple trades at prices ranging from $573.61 to $574.60. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 30, 2026 Filed May 1, 2026 20:56 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 880 | $573.00 | $504,244.05 |
DisclosureSEC source: 0001636178-26-000014 · primarydocument.xml · nonDerivative · entry 6 EDGEMOND JAMES · CIK 0001636178 · CFO AND TREASURER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 21,276 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on October 31, 2025. F6 · price: This transaction was executed in multiple trades at prices ranging from $572.61 to $573.40. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 30, 2026 Filed May 1, 2026 20:56 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 3,034 | $572.00 | $1,735,456.50 |
DisclosureSEC source: 0001636178-26-000014 · primarydocument.xml · nonDerivative · entry 5 EDGEMOND JAMES · CIK 0001636178 · CFO AND TREASURER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 22,156 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on October 31, 2025. F5 · price: This transaction was executed in multiple trades at prices ranging from $571.61 to $572.60. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 30, 2026 Filed May 1, 2026 20:56 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 2,940 | $571.23 | $1,679,420.02 |
DisclosureSEC source: 0001636178-26-000014 · primarydocument.xml · nonDerivative · entry 4 EDGEMOND JAMES · CIK 0001636178 · CFO AND TREASURER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 25,190 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on October 31, 2025. F4 · price: This transaction was executed in multiple trades at prices ranging from $570.61 to $571.57. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 30, 2026 Filed May 1, 2026 20:56 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 484 | $570.19 | $275,972.54 |
DisclosureSEC source: 0001636178-26-000014 · primarydocument.xml · nonDerivative · entry 3 EDGEMOND JAMES · CIK 0001636178 · CFO AND TREASURER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 28,130 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on October 31, 2025. F3 · price: This transaction was executed in multiple trades at prices ranging from $569.58 to $570.57. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 30, 2026 Filed May 1, 2026 20:56 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 262 | $569.24 | $149,141.85 |
DisclosureSEC source: 0001636178-26-000014 · primarydocument.xml · nonDerivative · entry 2 EDGEMOND JAMES · CIK 0001636178 · CFO AND TREASURER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 28,614 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on October 31, 2025. F2 · price: This transaction was executed in multiple trades at prices ranging from $568.58 to $569.48. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 30, 2026 Filed May 1, 2026 20:56 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionCommon Stock | 10,000 | $135.42 | $1,354,200.00 |
DisclosureSEC source: 0001636178-26-000014 · primarydocument.xml · nonDerivative · entry 1 EDGEMOND JAMES · CIK 0001636178 · CFO AND TREASURER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 28,876 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on October 31, 2025. Read SEC document |
| April 27, 2026 Filed Apr 28, 2026 21:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionStock Option · Derivative | 10,000 | $0.00 Strike: $135.42 | $0.00 |
DisclosureSEC source: 0001636178-26-000013 · primarydocument.xml · derivative · entry 9 EDGEMOND JAMES · CIK 0001636178 · CFO AND TREASURER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 52,500 Underlying: Common Stock · 10,000 shares Expires 2027-03-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on October 31, 2025. Read SEC document |
| April 27, 2026 Filed Apr 28, 2026 21:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 649 | $571.92 | $371,176.40 |
DisclosureSEC source: 0001636178-26-000013 · primarydocument.xml · nonDerivative · entry 8 EDGEMOND JAMES · CIK 0001636178 · CFO AND TREASURER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,876 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on October 31, 2025. F8 · price: This transaction was executed in multiple trades at prices ranging from $571.62 to $572.415. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 27, 2026 Filed Apr 28, 2026 21:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 1,755 | $571.10 | $1,002,273.30 |
DisclosureSEC source: 0001636178-26-000013 · primarydocument.xml · nonDerivative · entry 7 EDGEMOND JAMES · CIK 0001636178 · CFO AND TREASURER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 19,525 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on October 31, 2025. F7 · price: This transaction was executed in multiple trades at prices ranging from $570.62 to $571.605. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 27, 2026 Filed Apr 28, 2026 21:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 2,405 | $570.05 | $1,370,961.83 |
DisclosureSEC source: 0001636178-26-000013 · primarydocument.xml · nonDerivative · entry 6 EDGEMOND JAMES · CIK 0001636178 · CFO AND TREASURER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 21,280 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on October 31, 2025. F6 · price: This transaction was executed in multiple trades at prices ranging from $569.59 to $570.54. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 27, 2026 Filed Apr 28, 2026 21:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 1,107 | $569.01 | $629,899.38 |
DisclosureSEC source: 0001636178-26-000013 · primarydocument.xml · nonDerivative · entry 5 EDGEMOND JAMES · CIK 0001636178 · CFO AND TREASURER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 23,685 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on October 31, 2025. F5 · price: This transaction was executed in multiple trades at prices ranging from $568.55 to $569.53. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 27, 2026 Filed Apr 28, 2026 21:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 919 | $567.81 | $521,821.62 |
DisclosureSEC source: 0001636178-26-000013 · primarydocument.xml · nonDerivative · entry 4 EDGEMOND JAMES · CIK 0001636178 · CFO AND TREASURER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 24,792 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on October 31, 2025. F4 · price: This transaction was executed in multiple trades at prices ranging from $567.41 to $568.21. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 27, 2026 Filed Apr 28, 2026 21:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 1,449 | $566.73 | $821,190.90 |
DisclosureSEC source: 0001636178-26-000013 · primarydocument.xml · nonDerivative · entry 3 EDGEMOND JAMES · CIK 0001636178 · CFO AND TREASURER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 25,711 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on October 31, 2025. F3 · price: This transaction was executed in multiple trades at prices ranging from $566.36 to $567.35. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 27, 2026 Filed Apr 28, 2026 21:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 1,716 | $565.85 | $970,995.51 |
DisclosureSEC source: 0001636178-26-000013 · primarydocument.xml · nonDerivative · entry 2 EDGEMOND JAMES · CIK 0001636178 · CFO AND TREASURER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 27,160 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on October 31, 2025. F2 · price: This transaction was executed in multiple trades at prices ranging from $565.22 to $566.21. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 27, 2026 Filed Apr 28, 2026 21:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionCommon Stock | 10,000 | $135.42 | $1,354,200.00 |
DisclosureSEC source: 0001636178-26-000013 · primarydocument.xml · nonDerivative · entry 1 EDGEMOND JAMES · CIK 0001636178 · CFO AND TREASURER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 28,876 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on October 31, 2025. Read SEC document |
| April 23, 2026 Filed Apr 24, 2026 20:32 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionStock Option · Derivative | 10,000 | $0.00 Strike: $135.42 | $0.00 |
DisclosureSEC source: 0001636178-26-000012 · primarydocument.xml · derivative · entry 10 EDGEMOND JAMES · CIK 0001636178 · CFO AND TREASURER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 62,500 Underlying: Common Stock · 10,000 shares Expires 2027-03-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on October 31, 2025. Read SEC document |
| April 23, 2026 Filed Apr 24, 2026 20:32 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 120 | $576.62 | $69,194.00 |
DisclosureSEC source: 0001636178-26-000012 · primarydocument.xml · nonDerivative · entry 9 EDGEMOND JAMES · CIK 0001636178 · CFO AND TREASURER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,876 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on October 31, 2025. F9 · price: This transaction was executed in multiple trades at prices ranging from $576.45 to $576.93. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 23, 2026 Filed Apr 24, 2026 20:32 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 535 | $574.79 | $307,514.63 |
DisclosureSEC source: 0001636178-26-000012 · primarydocument.xml · nonDerivative · entry 7 EDGEMOND JAMES · CIK 0001636178 · CFO AND TREASURER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 19,360 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on October 31, 2025. F7 · price: This transaction was executed in multiple trades at prices ranging from $574.28 to $575.24. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 23, 2026 Filed Apr 24, 2026 20:32 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 321 | $573.51 | $184,097.32 |
DisclosureSEC source: 0001636178-26-000012 · primarydocument.xml · nonDerivative · entry 6 EDGEMOND JAMES · CIK 0001636178 · CFO AND TREASURER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 19,895 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on October 31, 2025. F6 · price: This transaction was executed in multiple trades at prices ranging from $573.22 to $574.09. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 23, 2026 Filed Apr 24, 2026 20:32 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 3,976 | $572.66 | $2,276,903.71 |
DisclosureSEC source: 0001636178-26-000012 · primarydocument.xml · nonDerivative · entry 5 EDGEMOND JAMES · CIK 0001636178 · CFO AND TREASURER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 20,216 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on October 31, 2025. F5 · price: This transaction was executed in multiple trades at prices ranging from $572.19 to $573.18. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 23, 2026 Filed Apr 24, 2026 20:32 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 3,325 | $571.64 | $1,900,714.97 |
DisclosureSEC source: 0001636178-26-000012 · primarydocument.xml · nonDerivative · entry 4 EDGEMOND JAMES · CIK 0001636178 · CFO AND TREASURER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 24,192 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on October 31, 2025. F4 · price: This transaction was executed in multiple trades at prices ranging from $571.19 to $572.18. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 23, 2026 Filed Apr 24, 2026 20:32 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 1,079 | $570.82 | $615,910.57 |
DisclosureSEC source: 0001636178-26-000012 · primarydocument.xml · nonDerivative · entry 3 EDGEMOND JAMES · CIK 0001636178 · CFO AND TREASURER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 27,517 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on October 31, 2025. F3 · price: This transaction was executed in multiple trades at prices ranging from $570.19 to $571.13. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 23, 2026 Filed Apr 24, 2026 20:32 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 280 | $569.63 | $159,495.11 |
DisclosureSEC source: 0001636178-26-000012 · primarydocument.xml · nonDerivative · entry 2 EDGEMOND JAMES · CIK 0001636178 · CFO AND TREASURER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 28,596 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on October 31, 2025. F2 · price: This transaction was executed in multiple trades at prices ranging from $569.19 to $570.17. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 23, 2026 Filed Apr 24, 2026 20:32 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionCommon Stock | 10,000 | $135.42 | $1,354,200.00 |
DisclosureSEC source: 0001636178-26-000012 · primarydocument.xml · nonDerivative · entry 1 EDGEMOND JAMES · CIK 0001636178 · CFO AND TREASURER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 28,876 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on October 31, 2025. Read SEC document |
| April 22, 2026 Filed Apr 24, 2026 20:32 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 364 | $575.85 | $209,607.62 |
DisclosureSEC source: 0001636178-26-000012 · primarydocument.xml · nonDerivative · entry 8 EDGEMOND JAMES · CIK 0001636178 · CFO AND TREASURER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,996 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on October 31, 2025. F8 · price: This transaction was executed in multiple trades at prices ranging from $575.30 to $576.26. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 20, 2026 Filed Apr 21, 2026 11:41 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionStock Option · Derivative | 10,000 | $0.00 Strike: $135.42 | $0.00 |
DisclosureSEC source: 0001636178-26-000011 · primarydocument.xml · derivative · entry 15 EDGEMOND JAMES · CIK 0001636178 · CFO AND TREASURER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 72,500 Underlying: Common Stock · 10,000 shares Expires 2027-03-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on October 31, 2025. Read SEC document |
| April 20, 2026 Filed Apr 21, 2026 11:41 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 238 | $585.36 | $139,316.20 |
DisclosureSEC source: 0001636178-26-000011 · primarydocument.xml · nonDerivative · entry 14 EDGEMOND JAMES · CIK 0001636178 · CFO AND TREASURER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,876 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on October 31, 2025. F14 · price: This transaction was executed in multiple trades at prices ranging from $585.09 to $585.80. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 20, 2026 Filed Apr 21, 2026 11:41 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 482 | $584.49 | $281,726.11 |
DisclosureSEC source: 0001636178-26-000011 · primarydocument.xml · nonDerivative · entry 13 EDGEMOND JAMES · CIK 0001636178 · CFO AND TREASURER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 19,114 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on October 31, 2025. F13 · price: This transaction was executed in multiple trades at prices ranging from $584.05 to $585.04. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 20, 2026 Filed Apr 21, 2026 11:41 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 1,009 | $583.55 | $588,797.31 |
DisclosureSEC source: 0001636178-26-000011 · primarydocument.xml · nonDerivative · entry 12 EDGEMOND JAMES · CIK 0001636178 · CFO AND TREASURER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 19,596 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on October 31, 2025. F12 · price: This transaction was executed in multiple trades at prices ranging from $583.035 to $584.02. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 20, 2026 Filed Apr 21, 2026 11:41 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 983 | $582.47 | $572,567.52 |
DisclosureSEC source: 0001636178-26-000011 · primarydocument.xml · nonDerivative · entry 11 EDGEMOND JAMES · CIK 0001636178 · CFO AND TREASURER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 20,605 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on October 31, 2025. F11 · price: This transaction was executed in multiple trades at prices ranging from $582.02 to $583.00. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 20, 2026 Filed Apr 21, 2026 11:41 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 488 | $581.66 | $283,851.06 |
DisclosureSEC source: 0001636178-26-000011 · primarydocument.xml · nonDerivative · entry 10 EDGEMOND JAMES · CIK 0001636178 · CFO AND TREASURER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 21,588 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on October 31, 2025. F10 · price: This transaction was executed in multiple trades at prices ranging from $581.01 to $582.00. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 20, 2026 Filed Apr 21, 2026 11:41 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 340 | $579.86 | $197,153.90 |
DisclosureSEC source: 0001636178-26-000011 · primarydocument.xml · nonDerivative · entry 9 EDGEMOND JAMES · CIK 0001636178 · CFO AND TREASURER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 22,076 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on October 31, 2025. F9 · price: This transaction was executed in multiple trades at prices ranging from $579.27 to $580.22. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 20, 2026 Filed Apr 21, 2026 11:41 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 500 | $578.90 | $289,451.95 |
DisclosureSEC source: 0001636178-26-000011 · primarydocument.xml · nonDerivative · entry 8 EDGEMOND JAMES · CIK 0001636178 · CFO AND TREASURER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 22,416 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on October 31, 2025. F8 · price: This transaction was executed in multiple trades at prices ranging from $578.26 to $579.23. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 20, 2026 Filed Apr 21, 2026 11:41 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 687 | $577.27 | $396,583.39 |
DisclosureSEC source: 0001636178-26-000011 · primarydocument.xml · nonDerivative · entry 7 EDGEMOND JAMES · CIK 0001636178 · CFO AND TREASURER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 22,916 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on October 31, 2025. F7 · price: This transaction was executed in multiple trades at prices ranging from $576.94 to $577.68. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 20, 2026 Filed Apr 21, 2026 11:41 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 1,398 | $576.37 | $805,771.69 |
DisclosureSEC source: 0001636178-26-000011 · primarydocument.xml · nonDerivative · entry 6 EDGEMOND JAMES · CIK 0001636178 · CFO AND TREASURER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 23,603 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on October 31, 2025. F6 · price: This transaction was executed in multiple trades at prices ranging from $575.92 to $576.91. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 20, 2026 Filed Apr 21, 2026 11:41 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 1,010 | $575.41 | $581,160.87 |
DisclosureSEC source: 0001636178-26-000011 · primarydocument.xml · nonDerivative · entry 5 EDGEMOND JAMES · CIK 0001636178 · CFO AND TREASURER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 25,001 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on October 31, 2025. F5 · price: This transaction was executed in multiple trades at prices ranging from $574.92 to $575.90. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 20, 2026 Filed Apr 21, 2026 11:41 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 442 | $574.09 | $253,746.63 |
DisclosureSEC source: 0001636178-26-000011 · primarydocument.xml · nonDerivative · entry 4 EDGEMOND JAMES · CIK 0001636178 · CFO AND TREASURER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 26,011 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on October 31, 2025. F4 · price: This transaction was executed in multiple trades at prices ranging from $573.90 to $574.80. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 20, 2026 Filed Apr 21, 2026 11:41 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 1,543 | $573.45 | $884,831.65 |
DisclosureSEC source: 0001636178-26-000011 · primarydocument.xml · nonDerivative · entry 3 EDGEMOND JAMES · CIK 0001636178 · CFO AND TREASURER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 26,453 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on October 31, 2025. F3 · price: This transaction was executed in multiple trades at prices ranging from $572.86 to $573.83. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 20, 2026 Filed Apr 21, 2026 11:41 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 880 | $572.33 | $503,648.64 |
DisclosureSEC source: 0001636178-26-000011 · primarydocument.xml · nonDerivative · entry 2 EDGEMOND JAMES · CIK 0001636178 · CFO AND TREASURER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 27,996 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on October 31, 2025. F2 · price: This transaction was executed in multiple trades at prices ranging from $571.79 to $572.75. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 20, 2026 Filed Apr 21, 2026 11:41 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionCommon Stock | 10,000 | $135.42 | $1,354,200.00 |
DisclosureSEC source: 0001636178-26-000011 · primarydocument.xml · nonDerivative · entry 1 EDGEMOND JAMES · CIK 0001636178 · CFO AND TREASURER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 28,876 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on October 31, 2025. Read SEC document |
| April 16, 2026 Filed Apr 17, 2026 20:56 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionStock Option · Derivative | 10,000 | $0.00 Strike: $135.42 | $0.00 |
DisclosureSEC source: 0001636178-26-000010 · primarydocument.xml · derivative · entry 11 EDGEMOND JAMES · CIK 0001636178 · CFO AND TREASURER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 82,500 Underlying: Common Stock · 10,000 shares Expires 2027-03-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on October 31, 2025. Read SEC document |
| April 16, 2026 Filed Apr 17, 2026 20:56 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 40 | $581.64 | $23,265.60 |
DisclosureSEC source: 0001636178-26-000010 · primarydocument.xml · nonDerivative · entry 10 EDGEMOND JAMES · CIK 0001636178 · CFO AND TREASURER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,876 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on October 31, 2025. Read SEC document |
| April 16, 2026 Filed Apr 17, 2026 20:56 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 160 | $581.08 | $92,973.20 |
DisclosureSEC source: 0001636178-26-000010 · primarydocument.xml · nonDerivative · entry 9 EDGEMOND JAMES · CIK 0001636178 · CFO AND TREASURER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,916 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on October 31, 2025. F9 · price: This transaction was executed in multiple trades at prices ranging from $580.62 to $581.45. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 16, 2026 Filed Apr 17, 2026 20:56 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 1,454 | $579.64 | $842,789.87 |
DisclosureSEC source: 0001636178-26-000010 · primarydocument.xml · nonDerivative · entry 8 EDGEMOND JAMES · CIK 0001636178 · CFO AND TREASURER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 19,076 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on October 31, 2025. F8 · price: This transaction was executed in multiple trades at prices ranging from $579.32 to $580.01. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 16, 2026 Filed Apr 17, 2026 20:56 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 1,066 | $578.83 | $617,029.48 |
DisclosureSEC source: 0001636178-26-000010 · primarydocument.xml · nonDerivative · entry 7 EDGEMOND JAMES · CIK 0001636178 · CFO AND TREASURER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 20,530 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on October 31, 2025. F7 · price: This transaction was executed in multiple trades at prices ranging from $578.32 to $579.31. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 16, 2026 Filed Apr 17, 2026 20:56 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 2,085 | $577.87 | $1,204,864.79 |
DisclosureSEC source: 0001636178-26-000010 · primarydocument.xml · nonDerivative · entry 6 EDGEMOND JAMES · CIK 0001636178 · CFO AND TREASURER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 21,596 F1 · kind: This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on October 31, 2025. F6 · price: This transaction was executed in multiple trades at prices ranging from $577.30 to $578.24. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.